PCRX (STOCKS)
Pacira BioSciences, Inc. Common Stock
$24.060000
+0.270000 (+1.13%)
Prev close: $23.790000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Frank D. Lee
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $972.97M
- Employees
- 790
- P/E (TTM)
- 152.30
- P/B (TTM)
- 1.41
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
6
Buy
3
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$0.57 | $0.92 | -0.3525 | -38.21% |
|
Sep 2025 (Q3)
|
$0.70 | $0.66 | +0.0351 | +5.28% |
|
Jun 2025 (Q2)
|
$0.74 | $0.72 | +0.0155 | +2.14% |
|
Mar 2025 (Q1)
|
$0.62 | $0.61 | +0.0121 | +1.99% |
Financial Statements
| Revenues | $726.41M |
| Benefits Costs and Expenses | $709.54M |
| Cost Of Revenue | $149.75M |
| Costs And Expenses | $707.22M |
| Gross Profit | $576.66M |
| Nonoperating Income/Loss | -$2.32M |
| Operating Expenses | $557.47M |
| Selling, General, and Administrative Expenses | $368.76M |
| Research and Development | $117.31M |
| Other Operating Expenses | $71.40M |
| Operating Income/Loss | $19.19M |
| Income/Loss From Continuing Operations After Tax | $7.03M |
| Income/Loss From Continuing Operations Before Tax | $16.87M |
| Income Tax Expense/Benefit | $9.84M |
| Income Tax Expense/Benefit, Current | $3.36M |
| Income Tax Expense/Benefit, Deferred | $6.48M |
| Net Income/Loss | $7.03M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $7.03M |
| Net Income/Loss Available To Common Stockholders, Basic | $7.03M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $0.16 |
| Diluted Earnings Per Share | $0.16 |
| Basic Average Shares | 44,566,000 |
| Diluted Average Shares | 45,042,000 |
| Assets | $1.26B |
| Current Assets | $547.97M |
| Inventory | $152.86M |
| Other Current Assets | $395.11M |
| Noncurrent Assets | $716.94M |
| Fixed Assets | $140.69M |
| Intangible Assets | $368.10M |
| Other Non-current Assets | $208.15M |
| Liabilities | $571.81M |
| Current Liabilities | $120.59M |
| Accounts Payable | $15.15M |
| Wages | $37.84M |
| Other Current Liabilities | $67.60M |
| Noncurrent Liabilities | $451.22M |
| Long-term Debt | $372.19M |
| Other Non-current Liabilities | $79.03M |
| Equity | $693.11M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $693.11M |
| Liabilities And Equity | $1.26B |
| Net Cash Flow From Operating Activities | $151.99M |
| Net Cash Flow From Operating Activities, Continuing | $151.99M |
| Net Cash Flow From Investing Activities | $99.48M |
| Net Cash Flow From Investing Activities, Continuing | $99.48M |
| Net Cash Flow From Financing Activities | -$369.63M |
| Net Cash Flow From Financing Activities, Continuing | -$369.63M |
| Exchange Gains/Losses | -$77.00K |
| Net Cash Flow | -$118.23M |
| Net Cash Flow, Continuing | -$118.15M |
| Comprehensive Income/Loss | $11.02M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $11.02M |
| Other Comprehensive Income/Loss | $11.02M |
| Other Comprehensive Income/Loss Attributable To Parent | $3.98M |